Abstract 590P
Background
Colorectal cancer (CRC) CRC with peritoneal metastasis (PM) obtain poor prognosis. Peritoneal Cancer Index (PCI) is used to evaluate the PM extent and selection of Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). However, PCI score assessed before surgery is not precise.We have developed a novel AI framework of DeAF (Decoupling feature alignment and fusion) to aid the selection and predict completeness of CRS in PM.
Methods
185 CRC patients with PM recruited from four tertiary hospitals were enrolled. The internal patient cohort was subsequently stratified into training and validation cohorts, comprising 84 and 30 individuals, respectively. Deep learning was used to train the DeAF model of Simsam algorithms by contrast CT images and then cooperate with clinicopathological parameters to increase the performance. The performance was evaluated by accuracy, sensitivity, specificity, and AUC by ROC in the internal and external validation cohorts.
Results
The AI model demonstrated a robust ability to predict the completeness of CRS with AUC of 0.9 in internal validation cohort. The model can predict whether patients are suitable for CRS. It can differentiate patients who would benefit from CRS. The model also showed high predictive performance of CRS completeness in external validation cohorts with AUC values of 0.906, 0.960, and 0.933, respectively (rounded to three decimal places).
Conclusions
The novel DeAF framework can aid surgeons to select proper patients for CRS and predict the completeness of CRS. The model can change surgical decision-making and provide potential benefits for patients with PM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
489P - Interfering with the tumor microenvironment of glioblastoma: An in vitro study
Presenter: Serena Mastantuono
Session: Poster session 16
490P - Inhibiting glioma cells' migration: Exploring Rho-GTPases as a potential therapeutic target
Presenter: Irene Giulia Rolle
Session: Poster session 16
Resources:
Abstract
491P - SRSF7 promotes glioblastoma progression via CDK1-mediated G2/M phase arrest of GBM cells
Presenter: Ya qin Hu
Session: Poster session 16
Resources:
Abstract
492P - Linking cellular drug responses to corresponding metabolomic tissue signatures in gliomas
Presenter: Stefanie Stanzer
Session: Poster session 16
493P - The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
Presenter: Kreina Vega Cano
Session: Poster session 16
494P - Effect of a new method for operating electric field patches on scalp reactions in glioblastoma patients receiving tumor treating fields
Presenter: Jinghui Liu
Session: Poster session 16
Resources:
Abstract
495P - Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: A single-center retrospective analysis of 118 cases
Presenter: Feng Chen
Session: Poster session 16
496P - Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients
Presenter: Ariane Steindl
Session: Poster session 16
497P - Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
Presenter: Junmin Song
Session: Poster session 16